Twelve‐Month Outcomes of Brolucizumab in Routine Clinical Practice: Fight Retinal Blindness! Registry
Eyes that switched from a first generation VEGF inhibitor to brolucizumab in routine clinical practice achieved a clinically significant extension of their treatment interval, with more than a third becoming inactive but with a relatively high rate of IOI.
Authors
- Alan Luckie
- Alessandro Invernizzi (ORCID: https://orcid.org/0000-0003-3400-1987)
- Jennifer Arnold
- Trung M. Dang
- Richard Barry (ORCID: https://orcid.org/0000-0002-0566-6667)
- Mariano Cozzi (ORCID: https://orcid.org/0000-0001-7777-2461)
- Hemal Mehta (ORCID: https://orcid.org/0000-0002-0606-9004)
- James Wong
- Yohei Hashimoto (ORCID: https://orcid.org/0000-0002-7944-6923)
- Samantha Fraser‐Bell (ORCID: https://orcid.org/0000-0001-5646-9359)
- Francesco Romano (ORCID: https://orcid.org/0000-0002-0458-9727)
- Vuong Nguyen (ORCID: https://orcid.org/0000-0001-9070-9803)
- Daniel Barthelmes
- Mark C. Gillies
Institutions
- The University of Sydney (AU)
- Royal Free London NHS Foundation Trust (GB)
- University of Milan (IT)
- University of Zurich (CH)
- Sydney Hospital (AU)
- Luigi Sacco Hospital (IT)
- University Hospital of Zurich (CH)
- Australian Pork (Australia) (AU)
- Sydney Hernia Specialists Clinic (AU)
- Albury Wodonga Health (AU)
- Retina Clinic (BR)
Publication Details
- Journal
- Clinical and Experimental Ophthalmology
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1111/ceo.70033
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00